



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Structural signature of the MYPT1-PP1 interaction

Citation for published version:

Pinheiro, AS, Marsh, JA, Forman-Kay, JD & Peti, W 2011, 'Structural signature of the MYPT1-PP1 interaction' Journal of the American Chemical Society, vol 133, no. 1, pp. 73-80., 10.1021/ja107810r

Digital Object Identifier (DOI):

[10.1021/ja107810r](https://doi.org/10.1021/ja107810r)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Journal of the American Chemical Society

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



Published in final edited form as:

J Am Chem Soc. 2011 January 12; 133(1): 73–80. doi:10.1021/ja107810r.

The Structural Signature of the MYPT1:PP1 Interaction

Anderson S. Pinheiro¹, Joseph A. Marsh³, Julie D. Forman-Kay³, and Wolfgang Peti^{1,2,\$}

¹ Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI 02903, USA

² Department of Chemistry, Brown University, Providence, RI 02903, USA

³ Molecular Structure & Function, Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada & Department of Biochemistry, University of Toronto, Toronto, Ontario M5S 1A8, Canada

Abstract

Muscle relaxation is triggered by the dephosphorylation of Ser19 in the myosin regulatory light chain. This reaction is catalyzed by the holoenzyme myosin phosphatase (MP), which includes the catalytic subunit protein phosphatase 1 (PP1) and the regulatory targeting subunit (MYPT). MYPT1 (myosin phosphatase targeting subunit 1) is responsible for both targeting the holoenzyme to subcellular compartments in the muscle and directing PP1 specificity towards myosin. In order to understand the molecular events leading to the MYPT1:PP1 holoenzyme formation, we used NMR spectroscopy to determine the structural and dynamic characteristics of unbound MYPT1. This allowed the conformations of MYPT1 in the free, unbound state to be directly compared to the PP1-bound state. Our results show that MYPT1₁₋₉₈ behaves like a two-domain protein in solution. The first 40 residues of MYPT1₁₋₉₈, the disordered region, are intrinsically disordered and highly dynamic, whereas residues 41–98, the folded ankyrin-repeat region, are well-structured and rigid. Furthermore, the integrated use of NMR and biophysical data enabled us to calculate an ensemble model for MYPT1₁₋₉₈. The most prominent structural feature of the MYPT1₁₋₉₈ ensemble is a 25% populated transient α -helix in the disordered region of MYPT1₁₋₉₈. This α -helix becomes fully populated when bound to PP1 and, as we show, likely plays a central role in the formation of the MYPT1:PP1 holoenzyme complex. Finally, this combined analysis shows that the structural and dynamic behaviors exhibited by MYPT1 for PP1 are distinct from those of any other previously analyzed PP1 regulatory protein. Collectively, these data enable us to present a new model of the molecular events that drive MYPT1:PP1 holoenzyme formation and demonstrate that there are structural differences in unbound PP1 regulators that have not been previously observed. Thus this work adds significant insights to the currently limited data for molecular structures and dynamics of PP1 regulators.

Keywords

NMR spectroscopy; ensemble calculations; MYPT1; intrinsically disordered protein

Department of Molecular Pharmacology, Physiology and Biotechnology & Department of Chemistry, Brown University, 70 Ship Street, GE-3, Providence, RI, 02912, USA; Phone 401-863-6084; Fax 401-863-6087, Wolfgang_Peti@brown.edu.

Supporting Information Available: Supplemental Figures (S1–S8) showing CD spectra, biochemical binding assay, 2D [¹H, ¹⁵N] HSQC of MYPT1₁₋₉₈, MYPT1₁₋₄₁, MYPT1₁₋₉₈ (C47S) and MYPT1₁₋₉₈ (A6C-MTSL), R₁ relaxation data and a sequence comparison of the MYPT family. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Introduction

Phosphorylation of myosin II regulates smooth muscle contraction, cell motility and cytokinesis, among many other essential biological functions^{1,2}. The responsible kinase is myosin light chain kinase, with myosin phosphatase (MP) identified as the counterpart phosphatase. The core enzyme of MP is Protein Phosphatase 1 (PP1), the most widely expressed and abundant Ser/Thr phosphatase, which is responsible for a large number of dephosphorylation reactions in humans. PP1 is a single domain enzyme (3 isoforms: α , β/δ , (two splicing products: γ_1 and γ_2); ~330 residues) that is exceptionally well conserved, from fungi to human, in both sequence and function³.

The catalytic site of PP1 contains two metal ions and is at the intersection of three putative substrate binding regions, referred to as the hydrophobic, acidic and C-terminal grooves³. The specificity of apo-PP1 is low. Nevertheless, *in vivo*, PP1 is able to dephosphorylate its substrates with high specificity. To achieve this specificity, PP1 interacts with a large number of regulatory proteins (~200 confirmed interactors)^{4–6}. Targeting proteins bind PP1 and direct its specificity by localizing PP1 to its point of action within the cell, as well as by directly altering its substrate preferences⁷, while inhibitor proteins directly inhibit the phosphatase activity of PP1. Most PP1 regulatory proteins ($\geq 95\%$) contain a primary PP1 binding motif [R/K][R/K][V/I]x[F/W], commonly referred to as the RVxF motif, which interacts with a binding region more than 20 Å away from the active site of PP1^{8,9}. It has become clear that this interaction is critical for the formation of a stable complex; however the RVxF motif itself does not play a major role in influencing the substrate specificity of PP1.

Only a very limited number of PP1 holoenzyme structures are currently available^{7,10,11}. The difficulty for structure determination of PP1 holoenzymes arises primarily from two factors: the instability of apo-PP1 in solution¹² and the high flexibility of most PP1 regulatory proteins¹³. Only a single structure of an inhibitor:PP1 (inhibitor-2:PP1^{10,14}) and three targeting protein:PP1 (MYPT1:PP1¹¹, spinophilin:PP1 and neurabin:PP1⁷) complexes have been reported. Recently, we have probed the structural properties of unbound PP1 regulatory proteins in significant detail. Inhibitor-2 (I-2), DARPP-32 and the PP1-binding domain of spinophilin are all intrinsically disordered in their unbound states^{7,13}. Ensemble modeling of these intrinsically disordered proteins, using large sets of experimental restraints, revealed diverse structural properties with both spinophilin and I-2 having partially formed α -helices (~25% populated for spinophilin, ~80% for I-2) that directly correspond to α -helices in their bound-state crystal structures¹⁴. Strikingly, spinophilin becomes completely ordered upon binding to PP1, while I-2 remains substantially disordered (~70%) in its PP1-bound state. Finally, diverse propensities for transient tertiary structure were observed, especially in spinophilin and I-2, which possess significant long-range contacts that are likely key for their biological functions.

The specificity of MP is primarily determined by the interaction of PP1 with the targeting protein MYPT (myosin phosphatase targeting subunit). Furthermore, a second protein, M20, can interact with MYPT, yet the function of M20 is currently unknown. The MYPT family comprises five members: MYPT1, MYPT2, MBS85, MYPT3 and TIMAP (ranked by degree of sequence identity with MYPT1). MYPT1 (myosin phosphatase targeting subunit 1), which is the most highly expressed subunit in smooth muscle cells, is a 110 kDa protein (residues 1-1030) that interacts with PP1 δ to form the MP holoenzyme. The crystal structure of the MYPT1 (residues 1-299):PP1 complex has been reported¹¹ (Figure 1A,B). In agreement with earlier reports, the N-terminal 40 residues of MYPT1 are critical for the interaction with PP1^{11,15}; however, additional MYPT1 regions, including the C-terminal ankyrin-repeats, contribute to PP1 binding. Thus, to gain information on the formation of the

MP complex, we used numerous biophysical and computational tools to determine the structural and dynamical characteristics of the unbound MYPT1 domain that are essential for PP1 regulation. We found that unbound MYPT1 can be split into two structurally distinct regions: the N-terminal 40 residues are intrinsically disordered (disordered region), while the rest of the protein remains folded in a conformation similar to that observed in the crystal structure (folded ankyrin-repeat region). The intrinsically disordered region contains a partially populated α -helix that corresponds perfectly to an α -helix that forms upon PP1 binding, as well as a locally extended region that corresponds to the functionally important RVxF motif. Finally, we integrate the various experimental measurements into an ensemble model calculation of partially disordered, partially folded MYPT1, similar to those performed previously for I-2, DARPP-32 and spinophilin. These calculations enable a detailed structural representation of the unbound state and further expand our knowledge of how these intrinsically disordered PP1 regulatory proteins direct PP1 activity.

Methods and Materials

Protein expression and purification

MYPT1 constructs 1-299, 1-98, and 1-41 (Figure 1) were subcloned into an in-house modified pET-28a vector (RP1B), which encodes a Thio₆His₆ expression/purification tag and a TEV protease cleavage site¹⁶. Wt-MYPT1 (amino acid construct residues 1-98) has a tendency to rapidly form dimers in solution, which can be reversed by the addition of large quantities of reducing reagent, such as DTT or TCEP. Mutation of Cys81 to Ser was introduced to circumvent dimerization of this construct. Interestingly, Cys47 does not have an effect on dimerization and thus was not mutated. Thus, all experiments conducted with MYPT1 construct 1-98 were performed using the mutant C81S, which is subsequently referred to as MYPT1₁₋₉₈. The plasmids were transformed into *Escherichia coli* strain BL21-Codon-Plus (DE3)-RIL (Stratagene). The expression of uniformly ¹⁵N- and ¹⁵N/¹³C - labeled proteins was carried out by growing freshly transformed cells in M9 minimal medium containing 1 g/L ¹⁵NH₄Cl and/or 4 g/L [¹³C]-D-glucose (CIL) as the sole nitrogen and carbon sources, respectively. Cells were grown at 37°C under vigorous shaking (250 rpm) in the presence of 34 µg/mL chloramphenicol and 50 µg/mL kanamycin until they reached an OD₆₀₀ of 0.6–0.8. Expression of His₆-MYPT1 constructs was induced by addition of 1 mM β -D-thiogalactopyranoside (IPTG) to the culture medium, and cultures were allowed to grow overnight (18 h) at 18°C under vigorous shaking (250 rpm). Cells were harvested by centrifugation and stored at –80°C.

The purification of all three MYPT1 constructs (1-299, 1-98, and 1-41) was performed as follows. Cells were resuspended in lysis buffer (50 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole, 0.1 % Triton-X 100, supplemented with EDTA-free protease inhibitor tablets (Roche)) and lysed by high-pressure homogenization (Avestin C-3 Emulsiflex). Cell debris was removed by centrifugation at 35000 \times g for 40 minutes at 4°C, and the supernatant containing soluble proteins was loaded onto a HisTrap HP column (GE Healthcare) equilibrated with 50 mM Tris pH 8.0, 500 mM NaCl, 5 mM imidazole. His₆-MYPT1 constructs were eluted with a 5–500 mM imidazole gradient. Fractions containing the protein of interest, as identified by SDS-PAGE gel electrophoresis, were pooled, incubated with His₆-TEV N1a (S219V) protease (in-house produced), and dialyzed against 50 mM Tris pH 7.5, 200 mM NaCl, until cleavage was complete. The untagged proteins were separated from the enzymatically-cleaved His₆ tag as well as from His₆-TEV by a Ni²⁺-affinity subtraction purification step using Ni-NTA beads (Qiagen). The proteins were subsequently purified by size-exclusion chromatography using a Superdex 75 26/60 column (GE Healthcare) equilibrated with 20 mM sodium phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP. Fractions containing the pure proteins, as identified by SDS-PAGE, were pooled and concentrated. All purifications were performed at 4°C. Phenylmethanesulfonyl fluoride

(PMSF), at a final concentration of 0.25 mM, and 10% D₂O were added to the final samples used for NMR measurements.

NMR measurements

All NMR experiments were acquired at 278 K (lowest stable temperature for cryoprobe used on our system) on a Bruker AvanceII 500 MHz spectrometer equipped with a TCI HCN-z cryoprobe. Proton chemical shifts were referenced directly to internal 3-trimethyl-silyl-1-propanesulfonic acid, sodium salt (DSS). ¹³C and ¹⁵N chemical shifts were referenced indirectly to DSS using the absolute frequency ratios.

Chemical Shift Assignment

The following spectra were used to achieve the sequence-specific backbone resonance assignments of MYPT1₁₋₉₈: 2D ¹H-¹⁵N HSQC, 3D HNCA, 3D HNCACB, 3D CBCA(CO)NH, 3D HNCO, 3D HN(CA)CO, 3D CC(CO)NH, 3D HBHA(CO)NH¹⁷. TopSpin 1.3 (Bruker) was used for data acquisition and processing. NMR spectra were analyzed with CARA (www.nmr.ch). Chemical shift assignments of MYPT1₁₋₉₈ were deposited in the BMRB data base (www.bmrb.wisc.edu) as entry 16160.

Secondary Structure Propensity

Secondary structure propensity (SSP) scores¹⁸ were calculated for MYPT1₁₋₉₈ using the RefDB¹⁹ random coil data base. A seven-residue moving-average window size, which excludes experimental data from residues before prolines, was used in the calculation.

Relaxation measurements

¹⁵N longitudinal (*R*₁) and transverse (*R*₂) relaxation rates and [¹H]-¹⁵N heteronuclear NOEs were measured as described previously²⁰. All spectra were performed with 2048 × 256 complex data points. The sweep widths of the ¹H and ¹⁵N dimensions were set to 12 and 26 ppm, respectively. *T*₁ experiments were acquired with relaxation delays (T) of 20, 100, 200, 300, 450, 600, 750, and 1000 ms. *T*₂ experiments were acquired with relaxation delays (T) of 20, 50, 100, 150, 200, 275, 350, and 450 ms. A recycle delay of 3 s between scans was used for all *T*₁ and *T*₂ experiments. [¹H]-¹⁵N NOEs were measured from a pair of spectra acquired with and without presaturation recorded in an interleaved manner. A recycle delay of 5 s between scans was used for NOE experiments.

Relaxation Data Analysis

All spectra were processed with NMRPipe version 97.027.12.56²¹ and analyzed with NMRView version 5.2.2.01²². *R*₁ and *R*₂ relaxation rates were determined by fitting the peak intensities as a function of the relaxation delays using a two-parameter monoexponential decay function, $I(T) = I_0 \exp(-R_{1,2}/T)$, where *I*(*T*) is the peak intensity after a time delay *T* and *I*₀ is the intensity at time zero. [¹H]-¹⁵N NOEs were calculated by dividing the intensity of the peaks in the spectra recorded without presaturation by the intensity of the peaks in the presaturated spectra.

Residual Dipolar Couplings

RDC measurements were performed with a 0.5 mM MYPT1₁₋₉₈ sample aligned in 5% (wt/vol) *n*-octyl-penta(ethylene glycol)/1-octanol (C₈E₅) (Sigma) dissolved in 20 mM sodium phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP²³. N-H RDCs (*D*_{NH}) were determined using the IPAP ¹⁵N-HSQC sequence^{24,25}. All spectra were performed with 2048 × 1024 complex data points. *D*_{NH} values were calculated as the difference between *D*_{NH}+*J*_{NH} measured in an aligned sample and *J*_{NH} measured in an isotropic sample. RDC analysis was performed using the program DIPOCOUP²⁶. RDC calculations/predictions within the

ENSEMBLE calculations were performed using the program PALES²⁷. Direct comparison of RDCs measured for unbound MYPT1₁₋₉₈ with best-fit (calculated) RDCs for MYPT1₁₋₉₈ taken from the MYPT1:PP1 crystal structure is, as expected, not ideal, but show the anticipated measure of agreement.

Circular Dichroism Spectroscopy

Far-UV circular dichroism (CD) measurements were recorded using a Jasco J-815 spectropolarimeter, in a 2 mm optical path quartz cell (Hellma), using either a 5 μ M MYPT1₁₋₂₉₉ or a 10 μ M MYPT1₁₋₉₈ sample (20 mM Na-phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP) at 4°C. All spectra were acquired from 260 to 195 nm, with a scan speed of 50 nm/min, 5 accumulations and a response time of 2 s. Equivalent spectra of buffers were recorded and subtracted from the protein spectra. Thermal denaturation experiments were performed at 220 nm with a temperature ramp of 1°C/min that was established using a Peltier temperature control unit.

Dynamic Light Scattering

DLS measurements were performed with a 100 μ M MYPT1₁₋₉₈ sample (20 mM Na-phosphate pH 6.8, 50 mM NaCl, 0.5 mM TCEP) using a Viscotek model 802 dynamic light scattering instrument at 4°C. The hydrodynamic radius (R_h) of MYPT1₁₋₉₈ was calculated using the Viscotek measurement software. All DLS measurements were performed immediately following elution of MYPT1 from a SEC column to ensure that no soluble aggregates or impurities interfere with the measurements.

MYPT1-PP1 complex formation

PP1 α production was described previously¹². *Escherichia coli* strain BL21 (DE3) (Invitrogen) cells expressing His₆-PP1 α ₁₋₃₃₀ were resuspended in lysis buffer (50 mM Tris pH 8.0, 700 mM NaCl, 5 mM imidazole, 1 mM MnCl₂, 0.1 % Triton-X 100, supplemented with EDTA-free protease inhibitor tablets (Roche)) and lysed by high-pressure homogenization (Avestin Emulsiflex C-3). Cell debris was removed by centrifugation at 97000 $\times g$ for 40 minutes at 4°C, and the supernatant containing His₆-PP1 α ₁₋₃₃₀ was loaded onto Ni-NTA beads (Qiagen) equilibrated with buffer A (50 mM Tris pH 8.0, 700 mM NaCl, 5 mM imidazole, 1 mM MnCl₂). The beads were washed with low salt buffer A (50 mM Tris pH 8.0, 50 mM NaCl, 5 mM imidazole, 1 mM MnCl₂) and consequently incubated with purified MYPT1₁₋₉₈ for 1 h at 4°C under slow shaking in order to allow for binding. MYPT1₁₋₉₈ co-eluted with His₆-PP1 α ₁₋₃₃₀ from the Ni-NTA beads upon wash with buffer B (50 mM Tris pH 8.0, 50 mM NaCl, 500 mM imidazole, 1 mM MnCl₂). Since only PP1 α ₁₋₃₃₀ was his-tagged, co-elution of both proteins confirms that MYPT1₁₋₉₈ forms a complex with PP1 α ₁₋₃₃₀, indicating a strong interaction, as previously detected for PP1 targeting protein complexes^{7,28,29}.

Calculation of MYPT1 ensemble model

A model of unbound MYPT1₁₋₉₈ was calculated using the program ENSEMBLE³⁰⁻³². The folded ankyrin-repeat region (residues 41-98) was kept identical to the published crystal structure, while the disordered N-terminal region (residues 1-40) was allowed to vary in conformation. ¹³C α , ¹³C β , ¹³C', ¹H α , ¹H^N and ¹⁵N chemical shift restraints and ¹⁵N R_2 restraints were applied to residues 1-40 (Table 1). The overall R_h was restrained for the full protein. ¹⁵N-¹H RDC restraints were used for the full protein. RDCs were restrained by averaging the values calculated using independent global alignment of each conformer with the program PALES²⁷. Note that this differs from the local alignment approach used previously³³ because the model calculated here contains both a folded and a disordered region. Thus both folded and disordered regions contribute to the alignment of each

molecule. Six independent ensembles were calculated using the simplest ensemble approach³², in which ensembles with the fewest number of structures that fit all of the experimental restraints are calculated. Each of the six final ensembles contained between 21–27 structures. Cluster analysis was performed using the NMRClust algorithm³⁴ and the distance matrix root mean square deviation.

A “statistical coil model” of MYPT1₁₋₉₈ was created by the program TraDES³⁵ to generate random structures for the N-terminal residues 1–40 using the ‘Coil’ sampling distribution³³. These structures were coupled with residues 41–98 from the crystal structure. Resulting models with steric clashes were discarded. A total of 5000 structures without steric clashes were generated.

Results

Three MYPT1 constructs (Figure 1), MYPT1₁₋₂₉₉ (identical to the construct used for crystal structure determination), MYPT1₁₋₉₈ and MYPT1₁₋₄₁ (disordered region) were expressed in *E. coli* and purified to homogeneity. Stability and folding of these MYPT1 fragments were determined using CD spectropolarimetry. As expected, MYPT1₁₋₂₉₉ shows a CD spectrum typical of a well-folded α -helical protein with a melting temperature of $48 \pm 2^\circ\text{C}$ (Supplemental Figure S1A). MYPT1₁₋₉₈ has a similar CD spectrum at low temperature (melting temperature of MYPT1₁₋₉₈ was determined to be $25 \pm 2^\circ\text{C}$) (Supplemental Figure S1B). Based on the melting temperature results, all NMR-based studies with MYPT1₁₋₉₈ were performed at 5°C , DLS measurements were performed at 4°C . Complex formation of MYPT1₁₋₉₈ with PP1 was used as a functional assay to ensure that biologically relevant, active protein constructs were used in this study (Supplemental Figure S2). Lastly, it was previously shown that an MYPT1 peptide (residues 1–38) binds PP1 with a K_d of $\sim 45 \text{ nM}$ ¹⁵. Taken together, MYPT1₁₋₉₈ was chosen for further detailed studies as it shares many of the characteristics of MYPT1₁₋₂₉₉, including both a disordered region and a folded ankyrin repeat region, yet is very well-suited for high-quality NMR studies.

MYPT1₁₋₉₈ contains a folded and an intrinsically disordered region

Using heteronuclear multidimensional NMR spectroscopy, the sequence-specific chemical shift assignment of MYPT1₁₋₉₈ was completed (Supplemental Figure S3). Using the chemical shift-derived SSP analysis and fast time-scale ¹⁵N auto-correlated relaxation measurements, it became evident that MYPT1₁₋₉₈ behaves like a two-domain protein in solution (Figure 1&2). MYPT1 residues 1–40 form the disordered region, while MYPT1 residues 41–98 form the folded ankyrin-repeat region.

To further verify the two-region behavior of MYPT1₁₋₉₈, we produced MYPT1₁₋₄₁. By directly overlapping the 2D [¹H,¹⁵N] HSQC spectra of MYPT1₁₋₉₈ and MYPT1₁₋₄₁ it is readily evident that the NH cross-peaks of MYPT1₁₋₄₁ overlap well with the NH cross-peaks of amino acids 1–41 in the MYPT1₁₋₉₈ spectrum (Supplemental Figure S4). This shows that minimal interaction between the PP1-binding and the ankyrin-repeat domain of MYPT1₁₋₉₈ are expected in the unbound form.

Fractional secondary structure in the intrinsically disordered region

Our NMR data shows that in solution the free PP1-binding domain of MYPT1 has an intrinsically disordered region. However, it is possible to identify preferential secondary structure in this disordered region using SSP analysis (Figure 2A). First, MYPT1 residues 5–17 form a $\sim 25\%$ populated α -helix. Interestingly, these residues fold into a fully populated α -helix when bound to PP1¹¹. Furthermore, this helix has been previously identified to contain a PP1 consensus binding sequence (R-X-X-Q-[V/I/L]-[K/R]-X-[Y/W], where x can

be any residue), which is referred to as the myosin phosphatase N-terminal element or MyPhoNE⁵. As this sequence is also present in six other unrelated PP1 targeting proteins, it is likely that it plays a role in PP1 substrate selection. Second, residues 31-38 preferably populate the β -region of ϕ/ψ -conformational space. Residues 31-38 include residues ³⁵KVKF³⁸, the MYPT1 RVxF motif, the essential PP1 anchoring motif that is shared by >95% of all PP1 regulators. This is significant, as in all currently available structures the RXvF motif binds in an extended fashion into the PP1 RVxF binding groove. Collectively, these data show that it is possible to identify two regions in the disordered region that exhibit preferred ϕ/ψ -space populations. Interestingly, both regions play a role in the formation of the PP1:MYPT1 holoenzyme and, based on our analysis of the structure of unbound MYPT1, seem to be primed for rapid complex formation. Therefore, providing the binding on-rates exceed the rates of interconversion between different MYPT1 conformations, MYPT1 most likely binds to PP1 through a conformational selection mechanism.

Preferred conformations and restricted dynamics

To gain additional insights into MYPT1's preferred transient structure, auto-correlated ¹⁵N R_1 , R_2 and ¹⁵N[¹H]-NOE relaxation data were recorded (Figure 2B,C and Supplemental Figure S5). The interpretation of relaxation rates in highly flexible proteins, such as the disordered region of MYPT1, is different from that in structured proteins because internal motions in structured proteins occur on a different time scale from that of the overall tumbling motion of the protein. Thus, there is an obvious difficulty in differentiating "internal" and "overall tumbling" motion in disordered proteins. Consequently, we focus on the qualitative analysis of R_2 values since they are especially sensitive to local structure variations.

The average R_2 rate for the flexible N-terminal disordered region is 8.4 ± 1.8 Hz, while it is 17.8 ± 2.2 Hz for the folded ankyrin-repeat region, again highlighting the two-domain behavior, as already described above. Reduced flexibility can be identified in the ~25% populated N-terminal helix. Interestingly, and in difference with other studied PP1 regulatory proteins^{7,13}, the ¹⁵N[¹H] NOE is positive throughout the sequence.

Conformational sampling of the MYPT1 PP1-binding domain

Dynamic light scattering (DLS) reports a hydrodynamic radius of 20.7 Å for MYPT1₁₋₉₈. This radius corresponds to a globally folded protein with a molecular weight of ~18 kDa, which is ~7 kDa larger than expected, providing additional evidence of the extended behavior of the N-terminal disordered region. Furthermore, while $i, i+1$ ¹H^N-¹H^N NOE cross-peaks, typical for α -helical secondary structure elements, can be detected in the well-folded ankyrin-repeat region (residues 41-98) of MYPT1₁₋₉₈, no significant $i, i+1$ ¹H^N-¹H^N NOE cross-peaks are identified in the disordered region (residues 1-40).

Paramagnetic relaxation enhancement data are typically used to extract distance constraints for flexible protein regions. Paramagnetic spin-labels, such as the commonly used MTSL label, are attached to a free cysteine residue. MYPT1₁₋₉₈ contains a single cysteine residue at position 47 (the only other Cys in MYPT1, Cys81, had already been mutated to a Ser to prevent dimerization, see methods). However, MTSL spin-labeling of Cys47, as well as mutation of Cys47 to Ser, led to unfolding of the folded ankyrin-repeat region (Supplemental Figure S6). Mutation of other residues to cysteine in MYPT1₁₋₉₈ was possible (A6C and S20C). However, S20C did not express. A6C did express at a much lower level than MYPT1₁₋₉₈. MTSL spin-labeling led to an apparent mixture of labeled residues and/or additional conformations (based on significant chemical shift changes and

additional peaks in the 2D [^1H , ^{15}N] HSQC spectrum, Supplemental Figure S7), which makes the extraction of useful information impossible and thus was not pursued.

In order to provide additional structural insights, we probed the relative orientation of the two regions in MYPT1₁₋₉₈ by measuring residual dipolar couplings (RDCs) using a 5% C₈E₅/1-Octanol alignment medium (alignment tensor: $D_{\text{ax}}=7.99$ Hz and $R_{\text{h}}=0.41$) (Figure 3A). In the folded ankyrin-repeat region, the RDCs show a good correspondence with the ankyrin-repeat α -helices. In the disordered region, RDCs are primarily negative, with a peak closely matching the ~25% populated N-terminal α -helix, consistent with previous results showing a strong correlation between RDCs and secondary structure^{33,36}. In addition, there are strong negative RDCs for residues 23-40, which includes the RVxF motif (³⁵ KVKF³⁸), suggesting a significant deviation from random-coil behavior in this region, likely due to extended backbone conformations and/or the formation of tertiary contacts.

We compared our experimental RDCs to those calculated from MYPT1₁₋₉₈ taken from the MYPT1:PP1 crystal structure. In this case the N-terminal disordered region is folded into its complex-bound conformation (Figure 3B). Importantly, the experimental and calculated RDCs agree well for residues in the folded ankyrin-repeat region suggesting it adopts a similar structure in solution as in the crystal structure (Q-factor³⁷=0.51 for MYPT1 residues 41-98). The differences between the experimental and calculated RDCs are largest for residues 23-40, indicating that these residues adopt a different conformation when unbound in solution than they do when complexed to PP1. This is confirmed by a Q-factor analysis³⁷ for MYPT1 residues 1-40 where the Q-factor drastically increases to 0.90, and thus confirms that the N-terminal disordered region adopts a different overall conformation(s) in the free form, when compared to the crystal structure-based bound conformation.

Ensemble model of unbound MYPT1₁₋₉₈

To further understand the structure of unbound MYPT1 and to advance our insight into the interaction with PP1, ensemble models of unbound MYPT1₁₋₉₈ were calculated using the program ENSEMBLE. In the calculations of these models, the structure of the folded ankyrin-repeat region was kept identical to that in the crystal structure, while the N-terminal disordered region (residues 1-40) were allowed to adopt varying conformations, representative of its disordered nature. Six independent ensemble models were calculated using identical experimental restraints and parameters and the model presented below represents the combination of all six ensembles. Table 1 presents the agreement between experimental measurements and ensemble calculated properties.

The residue-specific secondary structure content of the ensembles, including the fraction of residues within the broad α , left- β and right- β regions of Ramachandran space (previously defined³²) and the fraction of residues identified as α -helical by STRIDE³⁸ are presented in Figure 4A. The most notable secondary structure element observed is a ~25% populated α -helix in the N-terminal disordered region of MYPT1, similar to that seen from chemical shift analysis (Figure 2A). This helix becomes 100% populated in the MYPT1:PP1 holoenzyme structure.

To further assess the quality of the ensemble calculation, the experimental and ensemble-calculated RDCs were compared (Figure 4B). This figure also shows a comparison of the experimental RDCs to those predicted for a 5000-structure “statistical coil model”, which was created by combining the folded ankyrin-repeat region structure with TraDES ‘Coil’ model³⁵ conformers representing the N-terminal disordered region. Conformers that led to steric clashes were removed. Clearly, the ensembles are highly consistent with the experimental RDCs for the N-terminal disordered region and also show good agreement with the folded ankyrin-repeat region of MYPT1₁₋₉₈. The poorer agreement of folded-region

RDCs in the statistical coil model relative to the calculated ensemble model (despite the fact that the structure of this region is identical), arises from the fact that, in the ENSEMBLE calculations direct selection for agreement between ensemble-calculated and experimental RDCs is used. Lastly, the deviation of the statistical coil model from the experimental RDCs in the disordered region provides further evidence for the existence of substantial non-random structure in this region.

MYPT1 ensemble cluster analysis

Contact plots are a useful way to observe tertiary structure in proteins. However, in a highly dynamic and heterogeneous disordered-state ensemble, low populated contacts are often difficult to identify. Therefore, it is most useful to divide the ensembles into clusters of structurally similar conformers³². Tertiary structure analysis of each cluster, e.g. via tertiary contacts plots, can be much easier and more reliably performed. Although the ENSEMBLE calculations performed here did not include long-range NOE or PRE restraints that are typically used for defining tertiary contacts, RDCs can also contain useful information on tertiary structure, although their utility in this regard remains less defined³⁹. Thus, while the contact plots presented here provide hints as to the likely tertiary contacts in unbound MYPT1, they should be regarded with much less certainty than the secondary structure analysis.

Figure 5 shows the three highest populated clusters (A - 29%, B - 19%, C - 16%). In blue is the folded ankyrin-repeat region (residues 39-98), red is residues 1-19 and green is residues 20-38. The associated fractional contact plots are shown below (ENSEMBLE clusters on the top halves and the crystal structure on the bottom halves). Interestingly, all three clusters show some tertiary contacts between the disordered region and the folded ankyrin-repeat region, unlike MYPT1₁₋₉₈ in the crystal structure. The highest populated cluster shows a tight bundle of structures of the N-terminal fractionally populated α -helix. The additional clusters show less coherence and a much higher variance in the N-terminal α -helix. Taken together, this analysis correlates well with our experimental comparison of the 2D [¹H, ¹⁵N] HSQC spectrum of MYPT1₁₋₉₈ and MYPT1₁₋₄₁, where we detected only minimal differences. Notably, residue 6 is involved in significant contacts in clusters 2 (with residues 15-30) and 3 (with residues 15-35, 49-52, 71-74 & 82-84), which is interesting as spin-labeling of residue 6 led to the apparent formation of an alternate conformation in solution (Supplemental Figure S7). Therefore, it is tempting to speculate that these structural changes observed upon spin-labeling may be related to the disruption of contacts involving this region.

Discussion

A great wealth of functional data describing the biological importance of PP1, PP1 holoenzymes as well as either targeting or inhibitor proteins is readily available. However, information regarding their molecular structures is noticeably sparse. To date, all structurally analyzed PP1 targeting and inhibitor proteins fall into the class of intrinsically disordered proteins^{7,13,14,40-42}. Indeed, recently we predicted that at least 60% of all experimentally confirmed PP1 regulatory proteins are intrinsically disordered⁴. Previously, we and others described the inhibitor protein inhibitor-2 (I-2) in its free form, using NMR, SAXS data analysis and ensemble calculations, and its PP1-bound form, using NMR, SAXS data and X-ray crystallography^{10,14}. This analysis enabled us to detect a highly populated α -helix (~80%) in unbound I-2, which, in the PP1-bound form becomes 100% populated and, most significantly, blocks the PP1 active site. Interestingly, these residues in unbound I-2 have fast ps/ns timescale motions that are typical for a well-folded protein, as detected by ¹⁵N[¹H]-NOE experiments. However, while significantly populated secondary structure content seems to play a role in I-2:PP1 recognition, no significant tertiary contacts

resembling the bound conformation were identified in the ensemble analysis. Interestingly, Trp46, the aromatic residue in the I-2 RVxF motif, formed a locus for hydrophobic collapse within unbound I-2, becoming partially buried rather than surface exposed and accessible for PP1 interaction. Nevertheless, the ~80% populated α -helix was not involved in the collapse and appears primed for interaction with PP1, emphasizing the importance of pre-populated secondary structure for the I-2:PP1 interaction.

This was in contrast to our analysis of the highly dynamic PP1-binding domain of the PP1 targeting protein spinophilin (virtually all residues have negative $^{15}\text{N}[^1\text{H}]$ -NOE values). While a relatively short, ~25% populated α -helix was identified in unbound spinophilin that corresponded to a helix observed in the crystal structure, a significant β -strand-like tertiary interaction was also detected. This is interesting, as residues in these β -strand regions form a β -sheet in the PP1-bound conformation of spinophilin, which extends an existing β -sheet in PP1⁷. Another distinguishing feature is that, while I-2 remains significantly disordered and only the helical elements become stabilized when in complex with PP1, spinophilin completely folds upon binding to PP1.

Taken together, different structural parameters play key roles for the IDPs I-2 and spinophilin in their interaction with PP1. Thus, it is of interest to compare them to structural features of the unbound MYPT1 PP1-binding domain and their influence on its interaction with PP1 (Figure 1). The most significant difference between I-2, spinophilin and the PP1-binding domain of MYPT1 is the fact that the MYPT1 PP1-binding domain is not completely intrinsically disordered. Rather, it behaves as a two-domain protein, with a folded ankyrin-repeat region, which forms the structured core of MYPT1. As identified in the MYPT1:PP1 complex structure, all ankyrin-repeats make interactions with PP1. In contrast, the N-terminal 40 residues of MYPT1 are highly dynamic forming a disordered region. However, $^{15}\text{N}[^1\text{H}]$ -NOE analysis showed that residues in the MYPT1 disordered region are more restricted on the ps-ns timescale than residues in I-2 or spinophilin. This two-domain behavior is likely true for the MYPT family of PP1-interacting proteins, based on primary sequence comparison and IUPRED⁴³ prediction of their PP1-binding domains (Supporting Figure S8).

Interestingly, the disordered region contains two MYPT1:PP1 interaction hallmarks: 1) the N-terminal MyPhoNE motif and 2) the RVxF PP1 binding motif⁵. As we observed using chemical shift analysis, both interaction motifs show a conformational bias towards their respective PP1-bound forms and most likely function as interaction anchors, potentially in a manner described in the theoretical “fly-casting mode” of protein:protein interaction⁴⁴. The increased flexibility of the disordered region of MYPT1 PP1-binding domain likely enhances its capture radius, possibly facilitating the molecular recognition of PP1. Conversely, the preformed transient structure in the disordered region of MYPT1 contributes to the specificity of its interaction with PP1, as well as possibly decreases the entropic penalty associated with the binding of intrinsically disordered proteins to their molecular targets.

Based on our data for the MYPT1 binding domain, we speculate on a kinetic model for the interaction of MYPT1 with PP1. It is well recognized that the RVxF motif interaction is a very strong, hydrophobic interaction that plays a significant role in the interaction of PP1-regulators with PP1. Indeed, the RVxF site:PP1 interaction increases the stability of PP1⁴⁵. Conversely, the MyPhoNE motif interaction contains both hydrophobic and electrostatic interaction residues: MYPT1 residues L14, W17 form hydrophobic interactions, while MYPT1 residues R10, Q13, R16 form electrostatic interactions. As electrostatic interactions are long-range and are often involved in the initiation of binding, it is possible that the electrostatic interactions formed by residues in the MyPhoNE helix create the initial

interaction site for the MYPT1:PP1 interaction, with the RVxF motif site forming a tight hydrophobic lock. While it is also possible that the stronger interaction of the RVxF motif leads to a faster binding on-rate, the MyPhoNE motif is more distant from the folded ankyrin-repeat region, possibly enlarging the capture radius of MYPT1 for PP1. This model correlates well with a previously SPR-detected biphasic interaction of MYPT1₁₋₃₈¹⁵. These distinct interaction sites may provide a more effective, faster “fly-casting”, as two rather than a single binding site are available to “reel in” PP1. Finally, our work highlights differences between unbound PP1 regulators, significantly adding to the very limited knowledge of the molecular structures and dynamics of PP1 regulators.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr. R. Dominguez for generously providing the MYPT1 plasmid. This work was supported by NIH (R01NS056128) to WP and the Canadian Institutes of Health Research to JDFK.

References

1. Ito M, Nakano T, Erdodi F, Hartshorne DJ. *Mol Cell Biochem.* 2004; 259:197–209. [PubMed: 15124925]
2. Matsumura F, Hartshorne DJ. *Biochem Biophys Res Commun.* 2008; 369:149–56. [PubMed: 18155661]
3. Goldberg J, Huang HB, Kwon YG, Greengard P, Nairn AC, Kuriyan J. *Nature.* 1995; 376:745–53. [PubMed: 7651533]
4. Bollen M, Peti W, Ragusa MJ, Beullens M. *Trends Biochem Sci.* 2010; 35:450–458. [PubMed: 20399103]
5. Hendrickx A, Beullens M, Ceulemans H, Den Abt T, Van Eynde A, Nicolaescu E, Lesage B, Bollen M. *Chem Biol.* 2009; 16:365–71. [PubMed: 19389623]
6. Meiselbach H, Sticht H, Enz R. *Chem Biol.* 2006; 13:49–59. [PubMed: 16426971]
7. Ragusa MJ, Dancheck B, Critton DA, Nairn AC, Page R, Peti W. *Nat Struct Mol Biol.* 2010; 17:459–64. [PubMed: 20305656]
8. Cohen PT. *J Cell Sci.* 2002; 115:241–56. [PubMed: 11839776]
9. Bollen M. *Trends Biochem Sci.* 2001; 26:426–31. [PubMed: 11440854]
10. Hurley TD, Yang J, Zhang L, Goodwin KD, Zou Q, Cortese M, Dunker AK, DePaoli-Roach AA. *J Biol Chem.* 2007; 282:28874–83. [PubMed: 17636256]
11. Terrak M, Kerff F, Langsetmo K, Tao T, Dominguez R. *Nature.* 2004; 429:780–4. [PubMed: 15164081]
12. Kelker MS, Page R, Peti W. *J Mol Biol.* 2009; 385:11–21. [PubMed: 18992256]
13. Dancheck B, Nairn AC, Peti W. *Biochemistry.* 2008; 47:12346–56. [PubMed: 18954090]
14. Marsh JA, Dancheck B, Ragusa MJ, Allaire M, Forman-Kay JD, Peti W. *Structure.* 2010; 18:1094–1103. [PubMed: 20826336]
15. Toth A, Kiss E, Herberg FW, Gergely P, Hartshorne DJ, Erdodi F. *Eur J Biochem.* 2000; 267:1687–97. [PubMed: 10712600]
16. Peti W, Page R. *Protein Expr Purif.* 2007; 51:1–10. [PubMed: 16904906]
17. Sattler J, Schleucher J, Griesinger C. *Progress in NMR Spectroscopy.* 1999; 34:93–158.
18. Marsh JA, Singh VK, Jia Z, Forman-Kay JD. *Protein Sci.* 2006; 15:2795–804. [PubMed: 17088319]
19. Zhang H, Neal S, Wishart DS. *J Biomol NMR.* 2003; 25:173–95. [PubMed: 12652131]
20. Farrow NA, Muhandiram R, Singer AU, Pascal SM, Kay CM, Gish G, Shoelson SE, Pawson T, Forman-Kay JD, Kay LE. *Biochemistry.* 1994; 33:5984–6003. [PubMed: 7514039]

21. Delaglio F, Grzesiek S, Vuister GW, Zhu G, Pfeifer J, Bax A. *J Biomol NMR*. 1995; 6:277–93. [PubMed: 8520220]
22. Johnson BA. *Methods Mol Biol*. 2004; 278:313–52. [PubMed: 15318002]
23. Ruckert M, Otting G. *J Am Chem Soc*. 2000; 122:7793–7797.
24. Permi P, Rosevear PR, Annala A. *J Biomol NMR*. 2000; 17:43–54. [PubMed: 10909865]
25. Ottiger M, Delaglio F, Bax A. *J Magn Reson*. 1998; 131:373–8. [PubMed: 9571116]
26. Meiler J, Peti W, Griesinger C. *J Biomol NMR*. 2000; 17:283–94. [PubMed: 11014592]
27. Zweckstetter M. *Nat Protoc*. 2008; 3:679–90. [PubMed: 18388951]
28. Huang HB, Horiuchi A, Watanabe T, Shih SR, Tsay HJ, Li HC, Greengard P, Nairn AC. *J Biol Chem*. 1999; 274:7870–8. [PubMed: 10075680]
29. Kim YM, Watanabe T, Allen PB, Lee SJ, Greengard P, Nairn AC, Kwon YG. *J Biol Chem*. 2003; 278:13819–28. [PubMed: 12574161]
30. Choy WY, Forman-Kay JD. *J Mol Biol*. 2001; 308:1011–32. [PubMed: 11352588]
31. Marsh JA, Neale C, Jack FE, Choy WY, Lee AY, Crowhurst KA, Forman-Kay JD. *J Mol Biol*. 2007; 367:1494–510. [PubMed: 17320108]
32. Marsh JA, Forman-Kay JD. *J Mol Biol*. 2009; 391:359–74. [PubMed: 19501099]
33. Marsh JA, Baker JM, Tollinger M, Forman-Kay JD. *J Am Chem Soc*. 2008; 130:7804–5. [PubMed: 18512919]
34. Kelley LA, Gardner SP, Sutcliffe MJ. *Protein Eng*. 1996; 9:1063–5. [PubMed: 8961360]
35. Feldman HJ, Hogue CW. *Proteins*. 2000; 39:112–31. [PubMed: 10737933]
36. Mohana-Borges R, Goto NK, Kroon GJ, Dyson HJ, Wright PE. *J Mol Biol*. 2004; 340:1131–42. [PubMed: 15236972]
37. Cornilescu G, Marquardt JL, Ottiger M, Bax A. *J Am Chem Soc*. 1998; 120:6836–6837.
38. Frishman D, Argos P. *Proteins*. 1995; 23:566–79. [PubMed: 8749853]
39. Bernado P, Bertocini CW, Griesinger C, Zweckstetter M, Blackledge M. *J Am Chem Soc*. 2005; 127:17968–9. [PubMed: 16366524]
40. Huang HB, Chen YC, Lee TT, Huang YC, Liu HT, Liu CK, Tsay HJ, Lin TH. *Proteins*. 2007; 68:779–88. [PubMed: 17510962]
41. Huang HB, Chen YC, Tsai LH, Wang H, Lin FM, Horiuchi A, Greengard P, Nairn AC, Shiao MS, Lin TH. *J Biomol NMR*. 2000; 17:359–60. [PubMed: 11014604]
42. Lin TH, Huang YC, Chin ML, Chen YC, Jeng HH, Lin FM, Shiao MS, Horiuchi A, Greengard P, Nairn AC, Huang HB. *J Biomol NMR*. 2004; 28:413–4. [PubMed: 14872138]
43. Dosztanyi Z, Csizmok V, Tompa P, Simon I. *Bioinformatics*. 2005; 21:3433–4. [PubMed: 15955779]
44. Shoemaker BA, Portman JJ, Wolynes PG. *Proc Natl Acad Sci U S A*. 2000; 97:8868–73. [PubMed: 10908673]
45. Egloff MP, Johnson DF, Moorhead G, Cohen PT, Cohen P, Barford D, Embo J. 1997; 16:1876–87. [PubMed: 9155014]





Figure 1.

Crystal structure of the MYPT1:PP1 complex (PDBid: 1S70). **(A)** PP1 is shown as a surface representation (light gray). The two Mn²⁺ ions present in the active site of PP1 are highlighted in light blue. MYPT1 is shown as a cartoon representation, and colored to illustrate the different constructs used in this study (see also Figure 1C): MYPT1₁₋₄₁ (red); MYPT1₁₋₉₈ (red and purple) and MYPT1₁₋₂₉₉ (red, purple and blue). MYPT1 ankyrin repeats are numbered 1 to 8; all ankyrin repeats make contacts with PP1; N-, C-terminal and MyPhoNE PP1-binding motif residues are annotated. **(B)** Same as A rotated by 90°. The RVxF motif is annotated. **(C)** 1D representation of MYPT1: MYPT1₁₋₂₉₉, MYPT1₁₋₉₈ and MYPT1₁₋₄₁. Ankyrin repeats are represented by gray boxes and numbered according to A. The MYPT1-specific RVxF motif (35 KVKF³⁸) is highlighted in black, N-terminal adjacent to the first ankyrin repeat. The N-terminal transient helix, part of the MYPT1 disordered region, is depicted in blue. Color-coded bars correlate directly with coloring of MYPT1 in Figure 1A,B.

**Figure 2.**

(A) Secondary structure propensity scores, (B) experimental R_2 relaxation rates, and (C) heteronuclear ^{15}N [^1H]-NOE measurements demonstrate the two-domain behavior of MYPT1₁₋₉₈ in solution. Cartoon representations above the SSP scores indicate presence of secondary structure based on the MYPT1:PP1 complex structure. A dashed line separates the two different regions of MYPT1₁₋₉₈, the N-terminal flexible region and the C-terminal folded ankyrin-repeat region, which constitute the MYPT1 PP1-binding domain. An element of transient structure and reduced backbone motion within residues 5-17 in the N-terminal disordered region can be readily identified by SSP scores greater than ~0.2, elevated R_2 rates and ^{15}N [^1H]-NOE values. This transient helix is colored in blue, which differentiates it from the fully populated α -helices of the ankyrin-repeat domain, colored in gray.




Figure 3.

(A) Experimental D_{NH} RDCs measured for MYPT1₁₋₉₈ in 5% C₈E₅/1-Octanol alignment medium. (B) Comparison of experimentally derived D_{NH} RDCs for MYPT1₁₋₉₈ free in solution (black) and calculated D_{NH} for MYPT1₁₋₉₈ in its complex-bound conformation (gray). Secondary structural elements, based on the MYPT1:PP1 complex crystal structure, are indicated using cartoon representations.




Figure 4.

(A) Secondary structure content of calculated ensembles for MYPT1₁₋₉₈. Lines represent the α -helix populations (green, populations in the α (red), and β (blue) regions of the Ramachandran diagram (regions defined in³²). Error bars show the standard deviations between the six independently calculated ensembles. (B) Agreement between experimental RDCs (blue) and RDCs calculated from the ensemble model (red) and a 5000-structure statistical coil model for residues 1-40 appended to the folded structure for 41-98 (green; details described in methods).




Figure 5.

The three most significantly populated clusters (A - 29%, B - 19%, C - 16%) and their fractional contact plots for MYPT1₁₋₉₈. Fractional contact plots represent the fractional formation of contacts between pairs of residues, with a contact being defined as any two heavy atoms being within 10 Å of each other. The upper halves of the contact plots show contacts present in the clusters while the lower halves show contacts present in PP1-bound MYPT1. Structures are colored as follows: ankyrin-repeat domain (residues 41-98) – blue; residues 1-20 red; residues 21-40 green.

Table 1

List of experimental restraints used in the MYPT1 ensemble model calculations and their agreement with the ensemble-predicted properties.

Restraint type	Number of restraints	Ensemble agreement ^a
¹³ C ^α chemical shifts	35	0.18 ppm
¹³ C ^β chemical shifts	34	0.22 ppm
¹³ C' chemical shifts	35	0.26 ppm
¹ H ^α chemical shifts	32	0.043 ppm
¹ H ^N chemical shifts	33	0.11 ppm
¹⁵ N chemical shifts	33	0.46 ppm
¹ H- ¹⁵ N RDCs	87	3.7 Hz
Hydrodynamic radius	1	0.92 Å
¹⁵ N <i>R</i> ₂	32	0.77

^a Ensemble agreement is the root mean square deviation between experimentally determined and ensemble-predicted values, except for ¹⁵N *R*₂ restraints where it is the Pearson correlation between experimental values and local contact density, as previously defined³².